Melanoma Clinical Decision Support

A standalone, open-source clinical decision support application for melanoma. Built as a React web app with full clinical logic, molecular profiling, and evidence-based treatment recommendations.

For educational and research purposes only. Not intended for clinical decision-making. Always consult a qualified healthcare provider.

---

Features

1. Patient Profile Management

• Age, sex, ECOG performance status
• Melanoma subtype (cutaneous, acral, mucosal, uveal, desmoplastic)
• AJCC staging (0 through IV M1a-M1d)
• Pathological features: Breslow depth, ulceration, sentinel lymph node status
• Molecular markers: BRAF (V600E/K/other), NRAS, c-KIT, LDH, PD-L1

2. Recurrence Risk Classifier

• Composite risk score from Breslow depth, ulceration, SLN status, and stage
• Visual probability gauge with risk categories
• Feature contribution waterfall chart

3. Treatment Recommendation Engine

Evidence-based pathways branching on molecular profile and stage:

• Stage III adjuvant: dabrafenib + trametinib, nivolumab, pembrolizumab
• Stage IV first-line: nivolumab + ipilimumab, nivolumab + relatlimab
• BRAF V600+: encorafenib + binimetinib, dabrafenib + trametinib
• NRAS mutant: binimetinib
• c-KIT mutant: imatinib
• Brain metastases: SRS ± immunotherapy
• Emerging: lifileucel TIL therapy

4. Survival Estimation

• Stage-calibrated survival with BRAF/LDH/ECOG/age modifiers
• Interactive SVG survival curve (120-month horizon)
• 1-year, 2-year, and 5-year survival probabilities

5. Molecular Profile Explainer

Seven markers (BRAF, NRAS, c-KIT, CDKN2A, TERT, PTEN, PD-L1) with plain-language explanations, therapies, and population frequencies.

Getting Started

git clone https://github.com/stefanm808/my-oncology-lite-app-demo.git
cd my-oncology-lite-app-demo
npm install
npm run dev

Build

npm run build

Clinical References

Reference	Topic
COMBI-AD — Long et al., NEJM 2017	Adjuvant dabrafenib + trametinib
CheckMate 238 — Weber et al., NEJM 2017	Adjuvant nivolumab
KEYNOTE-054 — Eggermont et al., NEJM 2018	Adjuvant pembrolizumab
CheckMate 067 — Larkin et al., NEJM 2015	Nivo + ipi first-line
RELATIVITY-047 — Tawbi et al., NEJM 2022	Nivo + relatlimab
COLUMBUS — Dummer et al., Lancet Oncol 2018	Encorafenib + binimetinib
COMBI-v — Robert et al., NEJM 2015	Dabrafenib + trametinib
NEMO — Dummer et al., Lancet Oncol 2017	Binimetinib for NRAS
C-144-01 — Chesney et al., JCO 2022	Lifileucel TIL therapy
CheckMate 204 — Tawbi et al., NEJM 2018	Brain metastases
NCCN Guidelines Melanoma v4.2024	Standard of care

License

MIT — see LICENSE